-
公开(公告)号：KR1020090090946A
公开(公告)日：2009-08-26
申请号：KR1020080016523
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00 , A61P35/00
CPC classification number: A61K39/39566 , A61K38/00 , Y10S514/885
Abstract: A composition for preventing and treating cervical cancer, which comprises lymphotoxin alpha/beta complex (LTalpha/beta) or lymphotoxin beta receptor (LTbeta-R) binding agent is provided to use an agent for preventing or treating cervical cancer by inducing the mucosa immune response. A composition for preventing and treating cervical cancer comprises limphotoxin alpha/beta complex or limphotoxin beta receptor binding agent as an active ingredient. The lymphotoxin alpha/beta complex is a surface lymphotoxin alpha/beta complex or recombinant soluble lymphotoxin alpha/beta complex. The lymphotoxin beta receptor is an antibody to lymphotoxin beta receptor. The antigen is polyclonal antibody or monoclonal antibody.
Abstract translation: 提供了一种用于预防和治疗宫颈癌的组合物，其包括淋巴毒素α/β复合物（LTα/β）或淋巴毒素β受体（LTbeta-R）结合剂，用于通过诱导粘膜免疫应答来预防或治疗宫颈癌 。 用于预防和治疗宫颈癌的组合物包含角光素α/β复合物或角叉松素β受体结合剂作为活性成分。 淋巴毒素α/β复合物是表面淋巴毒素α/β复合物或重组可溶性淋巴毒素α/β复合物。 淋巴毒素β受体是淋巴毒素β受体的抗体。 抗原是多克隆抗体或单克隆抗体。
-
公开(公告)号：KR100650384B1
公开(公告)日：2006-11-30
申请号：KR1020060070390
申请日：2006-07-26
Applicant: 전남대학교산학협력단 , 주식회사 굿셀라이프
IPC: C07K2/00
Abstract: A method for differentiating precursor natural killer cell into mature natural killer cell is provided to obtain large amount of the mature natural killer cell by treating the precursor natural killer cell with Axl receptor tyrosine kinase. The composition for inducing differentiation of precursor natural killer cell into mature natural killer cell is characterized in that it includes at least one ligand selected from the group consisting of antibody of Axl receptor tyrosine kinase(Axl), gamma-carboxylated growth-arrest specific gene6(Gas6) protein and protein S as a ligand of the Axl. The method comprises the steps of: (a) treating hematopoietic stem cell with interleukin-7, stem cell factor and Flt3 ligand to be differentiated into precursor natural killer cell; and (b) treating the precursor natural killer cell with at least one selected from the group consisting of antibody of Axl receptor tyrosine kinase(Axl), gamma-carboxylated growth-arrest specific gene6(Gas6) protein and protein S.
Abstract translation: 通过用Axl受体酪氨酸激酶处理前体天然杀伤细胞来提供将前体天然杀伤细胞分化为成熟天然杀伤细胞以获得大量成熟天然杀伤细胞的方法。 用于诱导前体天然杀伤细胞分化为成熟自然杀伤细胞的组合物的特征在于其包含至少一种选自Axl受体酪氨酸激酶抗体（Axl），γ-羧化生长抑制特异性基因6（ Gas6）蛋白和蛋白S作为Axl的配体。 该方法包括以下步骤：（a）用白细胞介素-7，干细胞因子和Flt3配体处理造血干细胞以分化成前体天然杀伤细胞; 和（b）用选自Axl受体酪氨酸激酶抗体（Axl），γ-羧化生长抑制特异性基因6（Gas6）蛋白质和蛋白质S中的至少一种处理前体天然杀伤细胞。
-
公开(公告)号：KR100967623B1
公开(公告)日：2010-07-05
申请号：KR1020080016523
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00 , A61P35/00
Abstract: 본 발명은 유효성분으로서 림포톡신 α/β 복합체(Lymphotoxin α/β Complex, LTα/β) 또는 림포톡신 β 수용체(Lymphotoxin β receptor, LTβ-R) 결합제를 포함하는, 자궁경부암 예방 또는 치료용 조성물에 관한 것으로서, 점막면역 반응을 효과적으로 유도함으로써 자궁경부암의 예방 또는 치료제로 유용하게 이용될 수 있다.
림포톡신, 림포톡신 α/β 복합체, LTα/β, 림포톡신 β 수용체, LTβ-R, 점막면역, 인유두종바이러스, HPV, E6, 자궁경부암-
公开(公告)号：KR1020090090952A
公开(公告)日：2009-08-26
申请号：KR1020080016531
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00
CPC classification number: A61K38/44 , A61K38/005 , A61K38/1774 , A61K39/395 , C12N15/62 , Y10S514/886
Abstract: A composition for regulating or detecting gamma-delta T cell or cytokines secreted by the gamma-delta T cell, which contains Axl receptor tyrosine kinase, its ligand or inhibitor is provided to regulate gamma-delta T cell and prevent or treat inflammatory bowl diseases (IBD). A composition for regulating gamma-delta T cell or a cytokine which is secreted by the gamma-delta T cell comprises an Axl receptor tyrosine kinase, its ligand or its inhibitor as an active ingredient. The composition is used for preventing and treating inflammatory bowel disease. A method for screening an agent for preventing and treating inflammatory bowel disease comprises: a step of adding a test compound in Axl receptor tyrosine kinase, its ligand or inhibitor; and a step of researching the influence of test compound on the expression or activation of Axl receptor tyrosine kinase, gamma-delta T cell, or cytokine secreted by the gamma-delta T cell.
Abstract translation: 提供用于调节或检测由含有Ax1受体酪氨酸激酶，其配体或抑制剂的γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物，以调节γ-δT细胞并预防或治疗炎性碗疾病（ IBD）。 用于调节由γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物包含Ax1受体酪氨酸激酶，其配体或其抑制剂作为活性成分。 该组合物用于预防和治疗炎症性肠病。 用于筛选用于预防和治疗炎症性肠病的药剂的方法包括：在Ax1受体酪氨酸激酶，其配体或抑制剂中加入测试化合物的步骤; 以及研究化合物对由γ-δT细胞分泌的Axl受体酪氨酸激酶，γ-δT细胞或细胞因子的表达或活化的影响的步骤。
-
公开(公告)号：KR1020090090944A
公开(公告)日：2009-08-26
申请号：KR1020080016520
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: A61K48/00 , A61K2039/585 , C12N9/12
Abstract: A method for screening therapeutic agent or suppressing tumor by regulating Axl signal is provided to increase the sensitivity of natural killer cell by the expression of LIGHT gene and induce apoptosis of tumor cell. A composition for suppressing tumor comprises LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry mediator on T cells) (TNFSF14) or its activator as an active ingredient. The activator is Axl receptor tyrosine kinase or its ligand. The Axl ligand is an antibody to Axl antibody, gamma-carboxylated Gas-6(growth-arrest specific gene 6) or protein S. The tumor is lymphatic tumor. A method for screening agent for suppressing or treating tumor comprises: a step of adding a test compound to a LIGHT (TNFSF14) or its activator; and a step of researching the influence of the test compound on the expression or activation of LIGHT or its activator.
Abstract translation: 提供通过调节Axl信号筛选治疗剂或抑制肿瘤的方法，以通过LIGHT基因的表达增加自然杀伤细胞的敏感性并诱导肿瘤细胞凋亡。 用于抑制肿瘤的组合物包括LIGHT（与蛋白D竞争结合于T细胞上的疱疹病毒进入介导蛋白的竞争性淋巴毒素样诱导蛋白）（TNFSF14）或其活化剂作为活性成分。 活化剂是Axl受体酪氨酸激酶或其配体。 Axl配体是Ax1抗体，γ-羧化气体-6（生长停滞特异性基因6）或蛋白S的抗体。肿瘤是淋巴瘤。 用于抑制或治疗肿瘤的筛选剂的方法包括：将测试化合物加入到LIGHT（TNFSF14）或其活化剂中的步骤; 以及研究化合物对LIGHT或其活化剂表达或活化的影响的一个步骤。
-
Patent Agency Ranking16.发明公开
公开(公告)号：KR1020090090935A
公开(公告)日：2009-08-26
申请号：KR1020080016505
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: C07K14/705 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A61K48/00 , C12N15/8509
Abstract: A composition for detecting or suppressing the expression of GA733-2 antigen containing TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) gene or protein is provided to use in the investigation of cancer cause, early diagnosis of cancer and development of therapeutic agent. A composition for suppressing the expression of GA733-2 antigen comprises a TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) gene or protein as an active ingredient. The expression of GA733-2 antigen in a biological sample is suppressed by adding TREM-2 gene or protein. A method for screening an agent for suppressing and treating cancer comprises: a step of adding a TREM-2 gene or protein or candidate drug which suppresses or treat cancer into transgenic animal which is transformed with TREM-2 gene; and a step of researching the influence of the candidate drug on the expression or activation of TREM-2 or GA733-2. The cancer is colon cancer.
Abstract translation: 提供了用于检测或抑制含有TREM-2（触发受体表达于骨髓细胞-2）基因或蛋白质的GA733-2抗原表达的组合物用于癌症原因的调查，癌症的早期诊断和治疗剂的发展 。 用于抑制GA733-2抗原表达的组合物包含TREM-2（以骨髓细胞-2表达的触发受体）基因或蛋白质作为活性成分。 通过添加TREM-2基因或蛋白质抑制生物样品中GA733-2抗原的表达。 用于筛选抑制和治疗癌症的药剂的方法包括：向TREM-2基因转化的转基因动物中加入抑制或治疗癌症的TREM-2基因或蛋白质或候选药物的步骤; 研究候选药物对TREM-2或GA733-2表达或激活的影响的一个步骤。 癌症是结肠癌。
-
公开(公告)号：KR1020090090918A
公开(公告)日：2009-08-26
申请号：KR1020080016480
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: A61K38/005 , A61K48/00
Abstract: A composition for preventing and treating cervical cancer, which contains AxL receptor tyrosine kinase inhibitor is provided to regulate the expression of human papilloma virus (HPV) type 16 E6 gene and reduce the proliferation and metastatic property of cancer cell. A composition for preventing and treating cervical cancer comprises an inhibitor of Axl receptor tyrosine kinase as an active ingredient. A method for screening an agent for preventing and treating cervical cancer comprises: a step of adding a test compound to the Axl receptor tyrosine kinase; and a step of researching the influence of the test sample to the expression or activation of Axl and selecting a compound which suppresses the expression or activation of Axl.
Abstract translation: 提供含有AxL受体酪氨酸激酶抑制剂的宫颈癌预防和治疗组合物，用于调节人乳头状瘤病毒（HPV）16型E6基因的表达，降低癌细胞的增殖和转移性。 用于预防和治疗宫颈癌的组合物包含Ax1受体酪氨酸激酶的抑制剂作为活性成分。 用于筛选预防和治疗宫颈癌的药剂的方法包括：将测试化合物加入到Ax1受体酪氨酸激酶中的步骤; 研究测试样品对Axl的表达或活化的影响并选择抑制Ax1表达或激活的化合物的步骤。
-
公开(公告)号：KR1020080008060A
公开(公告)日：2008-01-23
申请号：KR1020060067484
申请日：2006-07-19
Applicant: 전남대학교산학협력단
Abstract: A method for preparing a natural killer cell is provided to treat cancer by obtaining the adult natural killer cell from an adult stem cell. A method for preparing a natural killer cell comprises the steps of: (a) treating an adult stem cell derived from cord blood of human with IL-7, SCF and Flt3L to be differentiated into a natural killer precursor cell; and (b) treating the natural killer precursor cell with Gas6. A transfectant comprises a recombinant vector pcDNA3.1(+)-GAS6.
Abstract translation: 提供一种制备自然杀伤细胞的方法，通过从成体干细胞获得成年自然杀伤细胞来治疗癌症。 制备天然杀伤细胞的方法包括以下步骤：（a）用IL-7，SCF和Flt3L处理源自人脐血的成体干细胞以分化为天然杀伤细胞前体细胞; 和（b）用Gas6处理天然杀伤前体细胞。 转染子包含重组载体pcDNA3.1（+）-GAS6。
-
19.发明公开
公开(公告)号：KR1020070078562A
公开(公告)日：2007-08-01
申请号：KR1020060008942
申请日：2006-01-27
Applicant: 주식회사 굿셀라이프 , 전남대학교산학협력단
CPC classification number: C07K14/005 , A61K39/12 , A61K47/62 , C07K14/245 , C07K2319/00 , C12N15/63 , C12N2510/02 , C12N2710/20034
Abstract: A chimeric protein consisting of LTB(Escherichia coli heat-labile enterotoxin B subunit) and HPV16 E7(human papilloma virus type 16 E7) protein and use thereof are provided to produce a vaccine for preventing and treating cervical cancer capable of inducing an antibody specific to HPV16 E7 protein, and improve mucosa permeability of the vaccine by inducing mucosal immune response. The chimeric protein having the amino acid sequence of SEQ ID NO:6 consists of LTB wherein the signal peptide region is deleted, and HPV16 E6 protein. A vector E7-LTB/pET29a contains a recombinant gene encoding the chimeric protein having the nucleotide sequence of SEQ ID NO:5. The chimeric protein is produced by transforming Escherichia coli with the vector E7-LTB/pET29a to produce Escherichia coli BL21(DE3):E7-LTB/pET29a(KCTC 10895BP), culturing the Escherichia coli BL21(DE3):E7-LTB/pET29a(KCTC 10895BP), separating the chimeric protein from the cultured Escherichia coli, and removing endotoxin from the separated chimeric protein. An oral vaccine for preventing and treating cervical cancer comprises the chimeric protein as an effective ingredient.
Abstract translation: 提供由LTB（大肠杆菌热不稳定肠毒素B亚基）和HPV16 E7（人乳头瘤病毒16型E7）蛋白组成的嵌合蛋白及其用途，以制备用于预防和治疗宫颈癌的疫苗，该疫苗能够诱导特异于 HPV16 E7蛋白，并通过诱导粘膜免疫应答提高疫苗的粘膜通透性。 具有SEQ ID NO：6的氨基酸序列的嵌合蛋白由缺失信号肽区的LTB和HPV16E6蛋白组成。 载体E7-LTB / pET29a含有编码具有SEQ ID NO：5的核苷酸序列的嵌合蛋白质的重组基因。 通过用载体E7-LTB / pET29a转化大肠杆菌产生大肠杆菌BL21（DE3）：E7-LTB / pET29a（KCTC 10895BP），培养大肠杆菌BL21（DE3）：E7-LTB / pET29a （KCTC 10895BP），从培养的大肠杆菌中分离嵌合蛋白质，从分离的嵌合蛋白中除去内毒素。 用于预防和治疗子宫颈癌的口服疫苗包括嵌合蛋白作为有效成分。
-
公开(公告)号：KR1020060135280A
公开(公告)日：2006-12-29
申请号：KR1020050055143
申请日：2005-06-24
Applicant: 전남대학교산학협력단
IPC: C12N15/867
Abstract: Novel recombinant vectors are provided to be used for expressing triggering receptor expressed on myeloid cells 2b(TREM-2) which is expressed at the activity of natural killer cell and the differentiation process and plays important role on innate immunity. The recombinant vector pcDNA3.1-TREM-2 expresses TREM-2 involved with innate immunity. The recombinant vector pLXSN-TREM-2 expresses TREM-2 involved with innate immunity.
Abstract translation: 提供新的重组载体用于表达在骨髓细胞2b（TREM-2）上表达的触发受体，其以天然杀伤细胞的活性和分化过程表达，并对先天免疫起重要作用。 重组载体pcDNA3.1-TREM-2表达涉及先天免疫的TREM-2。 重组载体pLXSN-TREM-2表达涉及先天免疫的TREM-2。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.025 seconds)
